Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
3(30%)
Results Posted
71%(5 trials)

Phase Distribution

Ph phase_1
5
50%
Ph phase_2
5
50%

Phase Distribution

5

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
5(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(7)

Detailed Status

Completed7
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (50.0%)
Phase 25 (50.0%)

Trials by Status

active_not_recruiting220%
recruiting110%
completed770%

Recent Activity

3 active trials
Showing 5 of 10
completedphase_2

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

NCT04856085
completedphase_2

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

NCT04412863
completedphase_1

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

NCT05612581
active_not_recruitingphase_2

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

NCT05461170
completedphase_2

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

NCT04891770
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04856085Phase 2

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Completed
NCT04412863Phase 2

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Completed
NCT05612581Phase 1

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Completed
NCT05461170Phase 2

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Active Not Recruiting
NCT04891770Phase 2

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Completed
NCT05844228Phase 1

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Completed
NCT05484206Phase 1

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Recruiting
NCT06070051Phase 1

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Active Not Recruiting
NCT04507269Phase 2

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

Completed
NCT03672188Phase 1

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10